Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

SITC 2022: Immunity Hubs and Response to Immunotherapy in NSCLC
SITC 2022: Outcomes of Combination Therapy for Advanced NSCLC Stratified by KRAS Status
SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?
SITC 2022: First-Line Antigen Presenting Cell Activator Plus Pembrolizumab Under Study in NSCLC
SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?
FDA Approves Combination Immunotherapy Regimen Plus Chemotherapy for Metastatic Lung Cancer
SITC 2022: Use of Cell-Free DNA Monitoring to Predict Outcomes With Immunotherapy in NSCLC
ASTRO 2022: Can Clinical Variables Predict Polymetastasis in Oligometastatic NSCLC?
ASTRO 2022: Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage NSCLC
Cempilimab-rwlc Plus Chemotherapy Receives FDA Approval in NSCLC
ASTRO 2022: Is Radiotherapy Safe for Cardiac Structures in Patients With Locally Advanced NSCLC?
Neoadjuvant Use of Ipilimumab Plus Nivolumab and Chemoradiotherapy for NSCLC
ASTRO 2022: Overall Time of Chemoradiotherapy and Outcomes in Stage III Lung Cancer
ASTRO 2022: Phase III Trial Compares Radiotherapy Regimens for Early-Stage NSCLC
ASTRO 2022: 2-Year KEYNOTE-799 Update on Pembrolizumab Plus Chemoradiotherapy in Stage III NSCLC
Can Weight Gain Improve Clinical Outcomes for Patients With Advanced NSCLC?
Impact of Low-Dose CT Screening on Lung Cancer Incidence and Stage Migration
Overall Survival Analysis From Phase III JIPANG Trial in Nonsquamous Lung Cancer
Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC
Molecular Profiling of Patients With Progressive NSCLC After Osimertinib Treatment
FDA Grants Fast Track Designation to Sapanisertib in Treatment of Squamous Lung Cancer
Mechanisms Behind NSCLC Associated With Exposure to the Air Pollutant Particulate Matter
ASCO Quality 2022: Are Mortgage Denial Rates Associated With Receipt of Guideline-Concordant Care in Lung Cancer?
ESMO 2022: Novel Bispecific Antibody Plus Chemotherapy Under Study in NSCLC
Can a Liquid Biomarker Augment Early Screening for Lung Cancer?
ESMO 2022: ADAURA Update on Adjuvant Osimertinib in Completely Resected EGFR-Mutated NSCLC
ESMO 2022: Interim Results From DESTINY-Lung02 Trial of T-DXd in NSCLC
FDA Grants Regular Approval to Selpercatinib in Locally Advanced or Metastatic RET Fusion–Positive NSCLC
ESMO 2022: Long-Term Follow-up of Overall Survival From the POSEIDON Lung Cancer Trial
ESMO 2022: Outcomes With Pembrolizumab and PD-L1 Expression in Resected NSCLC
ESMO 2022: 5-Year Survival Update on Pembrolizumab Plus Chemotherapy for Squamous NSCLC
University of Chicago Joins Research Initiative to Develop AI Tools in Lung Cancer Treatment
ESMO 2022: 5-Year Update From KEYNOTE-189 on Pembrolizumab Plus Chemotherapy in NSCLC
Bevacizumab for Advanced NSCLC: DNA Methylation Signature as a Predictive Biomarker?
WCLC 2022: JAVELIN Lung 100 Trial of Avelumab Versus Chemotherapy for Advanced NSCLC
WCLC 2022: Radon Exposure and Prevalence of Molecular Alterations in NSCLC Across Europe
Pathogenic Germline Variants in Patients With Lung Cancer
WCLC 2022: Nonregional Lymph Nodes and Prognosis in Stage IV NSCLC
WCLC 2022: Early Data on Sotorasib Plus an SHP2 Inhibitor in KRAS-Mutated NSCLC
WCLC 2022: SHAWL Study Focuses on Sexual Dysfunction in Women With Lung Cancer
WCLC 2022: Noninferiority Trial of Lobar or Sublobar Resection for Peripheral NSCLC
WCLC 2022: Interim Analysis of Overall Survival With Atezolizumab in Resected NSCLC From IMpower010
T-DXd Receives Accelerated Approval From the FDA for Treatment of HER2-Mutant NSCLC
Capmatinib Granted Regular Approval by the FDA in Treatment of Metastatic NSCLC
WCLC 2022: Biomarker-Directed Study of Treatment Options in NSCLC After Immunotherapy
WCLC 2022: NELSON Trial Protocol Versus NLST Protocol in Lung Cancer Screening
COVID-19 Vaccination in Immune Checkpoint Inhibitor–Treated Patients With Lung Cancer in Japan
Overall Survival Update From NADIM Trial: Neoadjuvant Nivolumab Plus Chemotherapy for NSCLC
Use of Liquid Biopsies in Managing EGFR-Mutant and Resistant Lung Cancers
IFCT-1803 LORLATU Cohort Evaluates Lorlatinib in Advanced ALK-Rearranged NSCLC
Does Esophageal-Sparing Radiotherapy Reduce the Risk of Esophagitis in Advanced NSCLC?
CodeBreaK 201 Focuses on Sotorasib in First-Line Treatment of Stage IV NSCLC
Neoadjuvant Selpercatinib Under Study in Resectable RET Fusion–Positive NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy in Advanced Resectable NSCLC
Penn Medicine Receives $9 Million Award From NCI to Study Intraoperative Molecular Imaging
Pooled Analysis of Appropriate NSCLC Populations for First-Line Immunotherapy Plus Chemotherapy
Cabozantinib Plus Atezolizumab in Advanced Non–Small Cell Lung Cancer
ASCO 2022: Mobocertinib Versus Amivantamab-vmjw in Treatment of EGFR-Mutated NSCLC
ASCO 2022: Eftilagimod Alpha Plus Pembrolizumab in NSCLC
ASCO 2022: Amivantamab-vmjw Under Study in NSCLC With Primary MET Exon 14 Skipping Mutation
Baseline Body Mass Index and Outcomes in Chemoimmunotherapy-Treated Lung Cancer
Does Long-Term Exposure to Wildfires Increase the Risk for Lung Cancer?
ASCO 2022: Expanded Cohort Update on Larotrectinib for NTRK Fusion–Positive Lung Cancer
ASCO 2022: How Has Low-Dose Chest CT Screening Impacted the Incidence of Lung Cancer?
FDA Brief: Application Accepted for Pembrolizumab as Adjuvant Therapy Early-Stage NSCLC
ASCO 2022: CHRYSALIS-2 Update on Amivantamab-vmjw Plus Lazertinib in NSCLC
ASCO 2022: Pathologic Regression and Event-Free Survival With Nivolumab Plus Chemotherapy for NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.